Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Common Equity (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Common Equity for 16 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Common Equity rose 22.49% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 22.49% year-over-year, with the annual reading at $1.0 billion for FY2025, 22.49% up from the prior year.
  • Common Equity hit $1.0 billion in Q4 2025 for Ligand Pharmaceuticals, up from $950.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.0 billion in Q4 2025 to a low of $597.5 million in Q4 2022.
  • Historically, Common Equity has averaged $784.9 million across 5 years, with a median of $799.0 million in 2022.
  • Biggest five-year swings in Common Equity: decreased 27.24% in 2022 and later grew 25.94% in 2024.
  • Year by year, Common Equity stood at $821.2 million in 2021, then fell by 27.24% to $597.5 million in 2022, then increased by 17.31% to $700.9 million in 2023, then grew by 18.48% to $830.4 million in 2024, then increased by 22.49% to $1.0 billion in 2025.
  • Business Quant data shows Common Equity for LGNDZ at $1.0 billion in Q4 2025, $950.2 million in Q3 2025, and $827.3 million in Q2 2025.